STOCKHOLM and NEW YORK, April 4, 2018 /PRNewswire/ -- ITBMed announces the completion of an equity investment of up to $67 million, led by Mr. Pablo Legorreta, the founder and CEO of Royalty Pharma. This capital injection will be used to develop Siplizumab in its lead indication of...